Chugai Pharmaceutical struck a global license and collaboration with Rani Therapeutics to develop an oral product combining Rani’s Ranipill robotic oral delivery technology with a Chugai rare‑disease antibody. The deal carries potential payments and milestones of up to $1 billion and grants Chugai access to Rani’s ingestible robotic platform designed to deliver biologics into the small intestine. The partnership underscores continued industry interest in transforming parenteral biologics into orally administered therapies and could reshape convenience and adherence for chronic indications if clinical translation succeeds. Companies said the collaboration will fund development and commercialization; observers noted regulatory and manufacturing complexities for an oral biologic but flagged the deal as strategically significant for both firms.